Abstract
We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.
Original language | English (US) |
---|---|
Pages (from-to) | 1855-1868 |
Number of pages | 14 |
Journal | Antimicrobial Agents and Chemotherapy |
Volume | 60 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2016 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases